Overview

Phase I/II Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer

Status:
Completed
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to find the best dose of hydroxychloroquine (HCQ) when given in combination with regorafenib and entinostat.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania
Treatments:
Entinostat
Hydroxychloroquine